CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study

PHASE3CompletedINTERVENTIONAL
Enrollment

1,003

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

October 17, 2016

Study Completion Date

December 13, 2016

Conditions
Recurrent Upper-Respiratory Tract Infections
Interventions
DRUG

J022X ST

"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"

DRUG

Placebo

"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach~* First month: 4 consecutive days per week during 3 consecutive weeks~* 5 next months: 4 consecutive days per month at monthly intervals"

Trial Locations (24)

Unknown

Ancona

L’Aquila

Milan

Modena

Napoli

Roma

Varese

Kaunas

Panevezys

Vilnius

Lesznowola

Lublin

Ostrołęka

Warsaw

Węgrów

Wołomin

Bacau

Brasov

Bucharest

Constanța

Craiova

Sibiu

Moscow

Saint Petersburg

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT01948856 - CLEARI (Clinical Efficacy Assessment on Recurrent Upper-Respiratory Tract Infections) Study | Biotech Hunter | Biotech Hunter